论文部分内容阅读
CD22 is a sialic acid-binding immunoglobulin-like lectin(Siglec) that is highly expressed on B-cell lymphomas,and is a validated target for antibody and nanoparticle based therapeutics;However,such cell targeted therapeutics are limited by their complexity,heterogeneity and difficulties in producing.